Substance + claimed effects

Diaphragmatic breathing (DB) — also called abdominal, belly, or "lower-chest" breathing — is the pattern in which inspiration is driven primarily by descent of the diaphragm rather than by elevation of the upper rib cage and shoulders via accessory muscles (scalenes, sternocleidomastoid, upper trapezius, pectoralis minor). Mechanically, descent of the dome lowers intra-thoracic pressure and raises intra-abdominal pressure, displacing the abdominal wall outward; tidal volume increases and respiratory rate typically falls. The claimed consequences span six interrelated dimensions covered in this entry: (1) CO₂ tolerance — slower, fuller breathing raises end-tidal CO₂ and over weeks resets central chemoreceptor sensitivity (Russo 2017, Bernardi 2001); (2) autonomic balance — increased cardiac vagal activity, larger respiratory sinus arrhythmia (RSA), increased baroreflex sensitivity, lowered sympathetic outflow (Laborde 2022, Lehrer & Gevirtz 2014); (3) anxiety / stress / mood — reduced cortisol, lower negative affect, anxiolysis in healthy and clinical populations (Ma 2017, Hopper 2019, Balban 2023); (4) sleep — easier sleep onset via parasympathetic shift, less nocturnal arousal (indirect, via autonomic/HRV mechanisms; Brown & Gerbarg 2005); (5) vocal use — the diaphragm is the central engine of trained singing and sustained speech, controlling subglottal pressure and exhalation duration (Salomoni 2016); (6) postural mechanics — the diaphragm is a primary trunk stabiliser, contributing to intra-abdominal pressure and spinal stiffness independently of its respiratory role (Hodges & Gandevia 2000, Hodges & Gandevia 2000b). The substance also has cross-condition effects in COPD pulmonary rehab, hypertension, and GERD that are mostly downstream of (1)–(3) plus diaphragm-as-anti-reflux-barrier mechanics (Halland 2021, Cheng 2026, Cancelliero-Gaiad 2014).

Evidence by addressing question

mechanism

The diaphragm is a dome-shaped sheet of skeletal muscle innervated by the phrenic nerves (C3–C5). On contraction it flattens and descends ~1.5 cm in quiet breathing (up to ~7–10 cm in deep breathing), reducing intra-thoracic pressure and drawing air through the trachea; the lower ribs hinge outward via the "bucket-handle" action. The abdominal contents are displaced caudally and the abdominal wall protrudes — the hallmark of diaphragmatic breathing. Accessory chest breathing instead elevates the sternum and upper ribs via scalenes and sternocleidomastoid, recruiting muscles whose mechanical leverage on the rib cage is small and whose metabolic cost per litre of ventilation is high.

Three distinct mechanistic chains follow from a diaphragm-led pattern. (a) Gas-exchange and chemoreceptor reset. Slow, deep, diaphragmatic breaths shift ventilation toward better-perfused basal lung zones, increasing alveolar ventilation per breath and reducing wasted dead-space ventilation. End-tidal CO₂ rises modestly and the central chemoreflex resets toward higher tolerance over weeks of practice (Bernardi 2001, Russo 2017). (b) Cardio-respiratory coupling. At ~6 breaths/min — close to the cardiovascular resonance frequency, near 0.1 Hz Mayer waves — breathing entrains heart-rate and blood-pressure oscillations in phase, maximising respiratory sinus arrhythmia. The amplified RSA acts as repeated "exercise" of the baroreflex arc; chronic practice raises baroreflex sensitivity (BRS) by 30–50% in heart-failure and hypertensive cohorts (Bernardi 2002, Joseph 2005, Lehrer & Gevirtz 2014). (c) Vagal afferent signalling. Slow expiration stretches pulmonary mechanoreceptors and engages the parasympathetic arm of the autonomic nervous system; vagal afferents project to the nucleus tractus solitarius and onward to limbic and prefrontal structures, plausibly contributing to the observed anxiolytic and affect-regulation effects (Brown & Gerbarg 2005). Independently of breathing, the diaphragm is also a primary spinal stabiliser: tonic diaphragm activation pre-empts limb movement, contributing to intra-abdominal pressure that stiffens the lumbar spine (Hodges & Gandevia 2000, Hodges & Gandevia 2000b).

evidence

Anxiety / stress / mood. The Hopper et al. 2019 JBI systematic review (clinical trials through Jan 2018) concluded that DB lowers both physiological (cortisol, BP, HR) and self-reported psychological stress markers in healthy adults; effect sizes are moderate, intervention durations range from a single 20-min session to 9 months (Hopper 2019). The Ma et al. 2017 RCT (n=40, 8 weeks, 20 sessions of paced DB at ~4 breaths/min with real-time feedback) showed significantly reduced cortisol, reduced negative affect on PANAS, and improved sustained attention vs. controls (Ma 2017). The Balban/Huberman 2023 Cell Reports Medicine RCT (n=111, 5 min/day × 1 month) compared three breathwork patterns to mindfulness meditation; cyclic sighing (long exhale-emphasis) produced the largest mood improvement and largest reduction in resting respiratory rate (Balban 2023). The Brown & Gerbarg 2005 two-part review on Sudarshan Kriya yoga (a structured breath sequence built on diaphragmatic foundation) summarised RCTs in major depression, PTSD, and substance-use rehabilitation, with effect sizes comparable to first-line pharmacotherapy in several trials (Brown & Gerbarg 2005, Brown & Gerbarg 2005b).

Autonomic balance / HRV. The Laborde 2022 meta-analysis (k=223 studies) found that voluntary slow breathing moderately increases cardiac vagal HRV indices during the breathing session, with measurable carry-over after acute and multi-session protocols (Laborde 2022). The Lehrer & Gevirtz 2014 review of HRV biofeedback (HRVB) — which trains slow paced diaphragmatic breathing at each individual's resonance frequency (4.5–6.5 breaths/min in adults) — documents efficacy across asthma, depression, hypertension, irritable bowel, and pre-eclampsia, with HRV amplitude rising 4–10× during sessions (Lehrer & Gevirtz 2014).

Blood pressure. The 2026 Cheng meta-analysis (k=13 RCTs in hypertensive patients) reports pooled reductions of ~7.7 mmHg systolic and ~4.0 mmHg diastolic from voluntary slow-breathing programmes (Cheng 2026). The Chaddha 2019 meta-analysis is consistent with a modest BP reduction (Chaddha 2019). Joseph 2005 demonstrated acute BRS gains and BP reductions at 6 breaths/min in essential hypertension (Joseph 2005). Note: a 2022 review found that device-guided slow breathing alone did not always significantly lower BP — heterogeneity is real.

CO₂ tolerance and chemoreflex. Bernardi et al. 2001 showed that breathing at 6 breaths/min reduced the chemoreflex response to both hypoxia and hypercapnia (i.e., raised tolerance for low O₂ and high CO₂) and increased baroreflex sensitivity in healthy adults — the founding human demonstration of the chemoreceptor-reset mechanism (Bernardi 2001). A small 4-week Buteyko study reported a 53% rise in breath-hold time and a 10.7% rise in ventilatory CO₂ threshold (Courtney & Cohen 2008), though Buteyko literature broadly is methodologically thin.

Vocal use. Salomoni et al. 2016 measured breathing patterns in classical singers vs. untrained controls and quantified that singers contribute ~35% abdominal/diaphragmatic component vs. ~14% in untrained — a 2.5× difference, with the diaphragm controlling exhalation duration and subglottal pressure (Salomoni 2016). The pedagogical tradition of appoggio in Italian bel canto formalises this: trained singers slow the ascent of the diaphragm (eccentric inspiratory contraction during exhalation) to steady subglottal pressure across long phrases. The same applies to public speakers, voice actors, and wind-instrument players.

Postural mechanics. Hodges & Gandevia's series demonstrated that the diaphragm activates tonically as part of the core musculature pre-empting limb movement, contributing to intra-abdominal pressure and lumbar stability (Hodges & Gandevia 2000, Hodges & Gandevia 2000b). When respiratory demand is high (CO₂-loaded breathing) the postural function is gated off in favour of ventilation — a clinically relevant trade-off in chronic chest-breathers under stress, whose trunk stability suffers as a side-effect of dysfunctional respiratory recruitment.

COPD. Cancelliero-Gaiad 2014 documented acute increases in tidal volume and SpO₂ and decreases in respiratory rate during DB in COPD patients; DB is a standard component of pulmonary rehabilitation (Cancelliero-Gaiad 2014). Caveat: in severe COPD with diaphragm flattening from hyperinflation, DB can paradoxically increase work of breathing and dyspnoea; the literature is mixed and DB is not recommended universally in severe disease.

GERD. Halland et al. 2021 (high-resolution impedance manometry RCT) showed that postprandial DB raises lower-oesophageal-sphincter pressure relative to gastric pressure, cutting postprandial acid exposure from 11.8% to 5.2% — mechanistic confirmation that the crural diaphragm augments the anti-reflux barrier (Halland 2021). Multiple subsequent RCTs reproduce symptomatic improvement.

protocol

Protocol parameters from the literature converge on a narrow band. Rate: 4–7 breaths/min, with 6 breaths/min the modal target (one inhale + one exhale ≈ 10 s, the cardiovascular resonance period) (Russo 2017, Laborde 2022). Inhale:exhale ratio: exhale slightly longer than inhale (4-in / 6-out is the canonical Stanford prescription) — exhale-bias is the active ingredient for the parasympathetic shift in Balban 2023. Mode: nasal in, mouth or nose out; abdominal wall rises visibly, upper chest does not. Posture: seated upright or supine; for learning, supine with one hand on belly and one on chest gives proprioceptive feedback. Dose: trials use 5–20 min/day; the Ma 2017 protocol was 20 sessions over 8 weeks, Balban 2023 used 5 min/day × 30 days, Hopper review covers 1×20-min through 9 months. Resonance-frequency biofeedback variant: for HRV-trained users, find personal resonance (usually 5.5–6.5 breaths/min) using a paced breathing app with HRV display (Lehrer & Gevirtz 2014). Acute use for anxiety: a single physiological sigh (two short inhales through the nose, one long exhale through the mouth) drops respiratory rate and felt arousal within seconds (Balban 2023).

contraindications

Diaphragmatic breathing at normal rates is essentially universally safe — the substance is literally how humans evolved to breathe. The caveats are narrow. Severe COPD with hyperinflation: a flattened diaphragm operates at mechanical disadvantage and forced DB can increase work of breathing and dyspnoea; supervised assessment recommended (Cancelliero-Gaiad 2014). Hyperventilation-prone individuals: "deep breathing" can be misinterpreted as fast deep breathing, which worsens hypocapnia and panic; the prescription must explicitly be slow and full, not fast and full. Late pregnancy: mechanical constraint from the uterus on diaphragm excursion makes belly-rising DB uncomfortable; lateral-costal breathing is preferred. Active panic attack with paradoxical breathing: introducing volitional breath control mid-attack can paradoxically intensify symptoms in some patients; pursed-lip breathing or rebreathing into hands may be more reliable in-the-moment. Breath-retention protocols (Sudarshan Kriya, Wim Hof) have separate safety profiles involving syncope risk and are out of scope here.

misconceptions

(a) "Breathe deeply" is widely (mis)taught as "fill your chest with air". The intended cue is diaphragm descent, abdominal rise, slow rate — not maximum thoracic expansion. (b) The diaphragm cannot be "isolated" volitionally as a non-respiratory muscle — its activation in breathing is involuntary; what training changes is breathing pattern, posture, and accessory-muscle dominance. (c) DB is not the same as "deep breathing" exercises that emphasise depth and speed; speed is in fact the critical variable for autonomic effects, not depth alone (Russo 2017, Laborde 2022). (d) "Belly breathing" is a useful learning cue but anatomically the abdomen does not "breathe"; rib-cage lateral expansion (the bucket-handle action) should accompany the belly rise, not be suppressed. (e) The diaphragm has nothing to do with the solar plexus chakra; the effect on calm is autonomic, not metaphysical. (f) Singers do not "sing from the diaphragm" in the sense of pushing air out with it — the diaphragm is an inspiratory muscle; its training role in singing is eccentric control of exhalation (Salomoni 2016).

practicalities

Equipment is optional. A paced-breathing app (free) or a metronome at 6 cycles/min suffices. HRV-biofeedback hardware (HeartMath Inner Balance, Polar H10 with EliteHRV, Lief, Apollo) ranges from $100–300 and lets users find their resonance frequency, but is not required for benefit. The acquisition curve is days to weeks for the basic pattern, 4–6 weeks for it to feel automatic during low-stress moments, and months to years for transfer to high-stress moments. The biggest practical failure mode is treating it as a stand-alone "exercise" rather than the default ambient pattern; the goal is to displace chest-led breathing as the resting baseline, not just to perform a 5-min session per day.

history

Diaphragmatic breathing is the ancestral pattern of all mammals and the dominant pattern in human infants. It became a formalised training object in three traditions: (a) yogic pranayama (~5th century BCE through medieval Hatha texts), with techniques such as ujjayi and nadi shodhana built on diaphragmatic foundation; (b) Italian bel canto and operatic voice pedagogy (~17th century onward), formalised as appoggio (Salomoni 2016); (c) 20th-century clinical adaptations — Edmund Jacobson's progressive relaxation, autogenic training (Schultz, 1932), Lamaze childbirth breathing (1950s), pulmonary-rehab DB protocols (1960s onward), and HRV biofeedback (Lehrer, Vaschillo, ~2000). The Buteyko method (Konstantin Buteyko, USSR, 1950s) emphasises the opposite cue — breathe less, lighter — built on the same chemoreceptor-reset mechanism (Courtney & Cohen 2008). The Stanford / Huberman cyclic-sigh popularisation (~2023) is the most recent secular wrapper (Balban 2023).

stakes

Chronic accessory-muscle dominance (upper-chest breathing) is the default in a meaningful fraction of stressed adults and is implicated in: persistent neck/upper-trapezius tension and tension headaches; chronic mild hypocapnia with attendant cerebral vasoconstriction and "brain fog"; amplified sympathetic tone with measurable HRV depression; sleep-onset difficulty (sympathetic dominance at bedtime); and worsening anxiety/panic loops via the hyperventilation→hypocapnia→symptoms→fear feedback (Russo 2017, Brown & Gerbarg 2005). Prevalence of dysfunctional breathing patterns: ~6–12% of the general population by clinical estimates. The substance's "absence" is therefore not a missing benefit so much as an active background tax on autonomic balance, mood floor, and trunk mechanics.

payoff

Acute (single session, minutes): immediate drop in heart rate of 5–15 bpm, increased HRV amplitude up to 4–10× during the session (Lehrer & Gevirtz 2014), subjective calm. Short-term (days to weeks): faster sleep onset, lower baseline anxiety on PSS/STAI scales, modest BP drop (Ma 2017, Balban 2023). Medium-term (1–3 months): meaningful reductions in negative affect, cortisol, BP (the Cheng meta-analytic ~7.7/4.0 mmHg in hypertensives) (Cheng 2026), measurable baroreflex sensitivity improvement (Joseph 2005). Long-term (months–years): higher resting HRV (a known mortality predictor), reduced antihypertensive medication need in some patients, improved vocal endurance for professional users, less reflux for upright-GERD patients (Halland 2021).

failure-modes

(a) Practising as fast deep breathing rather than slow full breathing — induces hypocapnia, dizziness, and worsens anxiety. (b) Forcing the upper chest to stay completely still — produces mechanical tension and over-recruits the abdominal wall; rib-cage lateral expansion is desirable. (c) Treating DB as a 5-min/day discrete exercise without ambient transfer — sessions improve session-time HRV but resting baseline pattern doesn't shift. (d) Use during active panic before competence is built — volitional override of breathing during sympathetic surge can paradoxically heighten interoceptive panic; train in calm states first. (e) Confusing DB with breath-retention or hyperventilation protocols (Wim Hof, Tummo, holotropic) — those are distinct substances with their own risk profiles and effects.

The credibility range

Optimist case

Diaphragmatic / slow breathing is one of the cleanest, cheapest, lowest-risk interventions in the catalogue. The mechanism is over-determined: the cardiovascular resonance phenomenon at ~0.1 Hz is a hard biophysical fact, the baroreflex-sensitivity gain is reproducibly measurable, the chemoreceptor reset is documented in healthy adults and in chronic-heart-failure / hypertension cohorts (Bernardi 2001, Bernardi 2002, Joseph 2005). Multiple meta-analyses converge on real effects: BP reduction of ~7/4 mmHg (Cheng 2026) — clinically meaningful, larger than several pharmacologic strategies; HRV elevation during and after sessions (Laborde 2022); stress reduction by physiological and self-report measures (Hopper 2019). The Balban/Huberman 2023 RCT showed superiority of exhale-emphasised DB over mindfulness meditation for mood improvement with only 5 min/day for 30 days (Balban 2023). The substance is the operating mode evolution selected — the literature is documenting baseline, not magic. Costs are zero, side-effect profile is essentially nil, transferability across domains (sleep, anxiety, BP, voice, postural support) is unusually broad. Pragmatic case: there is no other intervention in the catalogue with this combination of free, safe, mechanistically rigorous, multi-system benefits.

Skeptic case

Most DB trials are small (n=20–100), short (days to weeks), and unblinded by design — controls receive obviously different treatments. Effect sizes for psychological outcomes are dominated by expectancy and ritual-of-self-care non-specific effects; HRV biofeedback meta-analyses show heterogeneity that's hard to reconcile (Laborde 2022). The 2022 Gonçalves meta found device-guided slow breathing did not significantly reduce BP vs. control — contradicting the more optimistic readings. Many "slow breathing" studies confound rate (the active ingredient) with depth and with diaphragmatic vs. chest recruitment; isolating "diaphragmatic" as a separate variable from "slow" is difficult and the literature mostly does not do it cleanly. The Buteyko evidence base is thin and methodologically poor; pranayama trials are confounded by yoga's other components. Hopper 2019 itself flags small samples, short durations, and high variability in protocol. Reader is largely paying for the slow rate; whether the diaphragmatic recruitment per se does anything beyond what slow breathing at any rib pattern would do is not cleanly established. Anxiety outcomes are particularly placebo-vulnerable. Long-term adherence is poor — the gap between "I should do this" and the integrated default pattern is large.

Author's call

This entry lands strongly on the optimist side, with two qualifications. The strong call: diaphragmatic, slow (4–6/min) breathing is a real, no-cost, mechanistically grounded intervention with cross-system benefits backed by converging evidence — BP (Cheng, Chaddha, Joseph), HRV/autonomic (Laborde, Lehrer, Bernardi), affect/cortisol (Ma, Hopper, Balban), reflux (Halland), and pulmonary rehab (Cancelliero-Gaiad). The qualifications: (a) the active ingredient is the slow rate at least as much as the diaphragmatic pattern — the article frames them together because they co-vary in practice, but the agent should not over-claim that pattern alone (at fast rate) delivers the autonomic effect. (b) Psychological-outcome effect sizes are real but smaller than the wellness literature implies; framing is "honest tool" not "transformation." Controversy is genuine but narrow (active-ingredient debate; some heterogeneous meta-analytic findings); evidence is strong on physiology, moderate on clinical outcomes.

Stakeholder + incentive map

• Commercial: Apnea/HRV-biofeedback device makers (HeartMath, Lief, Apollo Neuro, Muse), breathwork app vendors (Othership, Breathwrk, Calm, Headspace), wearable HRV platforms (Whoop, Oura, Garmin). Most incentive is to amplify near-term claims; quality varies.
• Academic / clinical: Cardiology (HRV and baroreflex research — Bernardi, Lehrer groups), pulmonology / rehab (COPD breathing retraining), gastroenterology (Halland's reflux work), voice/laryngology (singing pedagogy + voice clinics), psychiatry (Brown, Gerbarg, Huberman/Spiegel — non-pharmacologic adjuncts), biofeedback societies (AAPB).
• Cultural / community: Yoga / pranayama lineages (Art of Living / Sudarshan Kriya, Iyengar, Ashtanga schools), Buddhist meditation traditions, the Wim Hof community (related but distinct), the Huberman Lab podcast audience (cyclic sighing).
• Skeptic counter-incentive: Pharmaceutical industry (antihypertensives, anxiolytics — minor counter-pressure), evidence-based-medicine skeptics flagging confounded trials. Less organised counter-position because there's no money in dismissing it.

Population variability

Responders skew toward: people with current chest-led / accessory-muscle dominance (the largest deltas, since baseline is dysfunctional); hypertensive or pre-hypertensive adults (BP responses are population-dependent — normotensives show minimal BP change); chronic-anxiety populations; people with measurable autonomic dysregulation (low resting HRV). Non-responders or muted-responders: people whose baseline pattern is already diaphragm-dominant (athletes, trained singers, long-term meditators — the floor is already raised); severe-COPD patients with hyperinflation; advanced-pregnancy women (mechanical limit). Age: effect generalises across adult age bands; resonance frequency drifts slightly upward in smaller / older bodies but the principle holds. Gender: no robust difference in autonomic response; cultural pattern of "suck-in-the-belly" abdominal-wall tension may be more common in women in some demographics and represents a learning obstacle. Children: effective but resonance frequency is faster (6.5–9.5/min) (Lehrer & Gevirtz 2014).

Knowledge gaps

• Clean factorial dissection of rate vs. pattern (slow chest breathing vs. slow diaphragmatic vs. normal-rate diaphragmatic) — currently confounded in most trials.
• Long-term (>12 month) outcome data — almost everything is ≤6 months. Whether baseline pattern truly shifts permanently is empirically open.
• HRV-biofeedback hardware vs. unaided paced breathing head-to-head: small literature, mixed results.
• Optimal exhale:inhale ratios — exhale-bias is supported by the Stanford cyclic-sigh data but the dose-response curve is unmapped.
• Postural-mechanics outcomes (lower-back pain, athletic performance) clinically — Hodges/Gandevia established the mechanism, but RCTs of DB-as-back-pain-intervention are sparse and mostly bundled with broader physiotherapy.
• Sleep — surprisingly little dedicated trial work on DB as sleep-onset intervention specifically; mostly inferred from anxiety / HRV results.
• The mechanistic question of whether vagal afferent signalling (Polyvagal-style account) is causal or epiphenomenal to the observed mood effects.

Scope and narrowing. The brief named six consequences (CO₂ tolerance, autonomic balance, anxiety, sleep, vocal use, postural mechanics) and the article covers all six. The vocal-use consequence got the lightest treatment in the body — it lands inside misconceptions ("sing from your diaphragm" is anatomically backward) and inside payoff (vocal endurance) rather than getting its own addressing section, because the audience overlap with professional singers is small and the cleaner version of the substance for a generalist reader was the autonomic / mood / BP axis. CO₂ tolerance is woven through the mechanism section ("chemistry") rather than headlined, because the practical reader cue ("breathe slower") is the same regardless of the chemoreceptor-reset framing. Postural mechanics is named in mechanism ("structure") and the broader trunk-stability question is signposted in out-of-scope rather than expanded.

Rating difficulties.

• mood = 4 vs 5. Tempting to go 5 given Balban/Stanford beat mindfulness meditation and the SKY literature reaches first-line-treatment effect sizes for depression/PTSD. Held at 4 because (a) the strongest result is exhale-emphasis specifically, not all diaphragmatic patterns, (b) effect sizes for psychological outcomes carry expectancy load, (c) the 5-tier descriptor ("transformative; profound life-reorientation") is reserved for psychedelics / trauma-resolution interventions.
• evidence = 4 vs 5. Held at 4 because while there are multiple meta-analyses, the heterogeneity between them (2026 Cheng favourable, 2022 Gonçalves null for device-guided slow breathing) and the small-sample / unblinded structure of most RCTs prevents a clean 5. Mechanism is 5-tier; clinical-trial quality is 4-tier.
• longevity = 2. Real but indirect — via BP and HRV, both established mortality predictors. Not an exercise-equivalent, but not zero. Anchored at 2.
• health_short_term = 3. The cluster of weeks-timescale wins (BP, reflux, neck tension, sleep onset) collectively earns 3 even though no single one is a stand-alone 3.
• beauty_cumulative dropped from 1 to 0. Initial 1 reflected the indirect cortisol-and-sleep → complexion path. Dropped because (a) effect is too indirect to deserve a dedicated body paragraph, (b) score-and-body-track-each-other rule, (c) honest zeros make the high scores legible (per meta.md §5a). This entry isn't an aesthetic intervention; flagging it as one would mislead the rank card.
• controversy = 2. Genuine field disagreement is narrow: is the slow rate the active ingredient or rate-plus-pattern? Not a 3 because the disagreement isn't load-bearing for the practical recommendation.

Hard editorial call on the rate-vs-pattern framing. Throughout the article, "diaphragmatic breathing" and "slow breathing" are presented together because in practice they co-occur — you can't sustain six breaths/min on accessory muscles. The literature mostly studies the package. The credibility-range author's call (research §3c) flags this honestly; the article surfaces it once in the evidence section ("the active ingredient is the slow rate as much as the diaphragmatic pattern") and doesn't dwell on it further because deeper treatment would confuse the practical reader without changing the recommendation.

Separate-entry candidates.

• Heart-rate-variability biofeedback / resonance-frequency training — substantial enough literature (Lehrer, Vaschillo, Gevirtz) to warrant separate treatment focused on the hardware-augmented clinical version.
• Buteyko method — different cue ("breathe less, lighter"), distinct community, asthma applications.
• Cyclic sighing / physiological sigh — the Balban 2023 protocol is narrow enough and popularised enough to be addressable on its own.
• Singer's breath (appoggio) — for a voice-as-tool vertical, if one ever exists.
• Wim Hof / hyperventilation breathwork — explicitly separate substance, separate risk profile.
• Box breathing, Sudarshan Kriya — adjacent breathwork protocols with their own evidence trails.

Future-link candidates. Once they exist: nsdr, mouth-tape, sleep-apnea, hrv-biofeedback, cyclic-sighing, buteyko, uars. Pre-wired in related where reasonable guesses for the ids are available.

What was excluded.

• COPD pulmonary rehab dosed in detail — kept to the contraindication caveat. The clinical detail belongs in a dedicated pulmonary-rehab entry.
• Pranayama-specific taxonomies (ujjayi, nadi shodhana, kapalabhati, bhastrika). Mentioned only obliquely. Each deserves its own evaluation; lumping under "diaphragmatic breathing" would be a category error.
• Polyvagal-theory framing (Porges). The vagal-afferent mechanism in the research dossier nods to it; the article doesn't, because polyvagal-as-mechanism is contested among neuroscientists and the agnostic "parasympathetic shift" framing is sufficient.
• Specific HRV-biofeedback hardware comparisons — out of scope for a foundational entry, suited to a dedicated HRVB entry.
• Detailed trial-design vocabulary in the evidence section (specific cancellation tasks, primary endpoints, etc.). Compressed into the Ma 2017 science callout; deeper trial-by-trial reporting would push the section into literature-review voice.